There is now compelling evidence for tumour initiating or cancer stem cells (CSCs) in human cancers. Inherent in the CSC hypothesis is their dual role, as a tumour-initiating cell, and as a source of treatment-resistance. It seems that, employing traditional therapies targeted towards bulk populations alongside targeted CSC-specific drugs will provide best therapeutic benefits. However, the mechanisms behind therapeutic resistance in CSC are still not known.